#China #Jinan #Dental Innovation #Angelalign #A7

Angelalign Technology Inc. Appeals Ruling on Premolar Extraction Solutions

In a strategic move, Angelalign Technology Inc. (stock code: 6699.HK) has announced that it will appeal a recent ruling from the Intermediate People's Court in Jinan, China. The judgment, passed on August 10, 2026, mandates that Angel's Chinese subsidiaries cease using their advanced masterForce biomechanical simulation and digital diagnostic and design system, ATreat, to provide their A7 and A7 Speed premolar extraction solutions. The company firmly asserts that this ruling, which is effective solely in China, does not currently impact their customers or patients.

Understanding the Legal Context

The preliminary decision is contingent upon the outcome of Angelalign's appeal, which the company is optimistic about. Angelalign's stance is clear: it believes that its A7 premolar extraction solution does not infringe upon any valid patent. The company has a strong track record of winning patent litigation globally, reflecting its commitment to fair competition in the dental aligner and intraoral scanner markets.

Fox Hu, the CEO of Angelalign, reassured stakeholders by stating, "This court's ruling only applies within China. Even in China, it does not have any immediate implications for our clients." His confidence stems from the increasing interest orthodontists are showing in Angelalign's professional solutions globally. Hu is hopeful about winning the appeal, especially given that Angelalign has successfully navigated through similar cases in various jurisdictions, including a recent provisional ruling in Düsseldorf, Germany, which favored the company and rejected the plaintiff's request for preliminary measures against Angelalign’s A7 extraction solution.

A Legacy of Innovation

The current legal situation is part of a broader patent infringement lawsuit initiated by Align Technology Inc. (stock symbol: ALGN), which Angelalign vehemently contests. As a company, Angelalign has a proud history of intellectual property respect and innovation that spans over two decades. Many leading orthodontists, including competitors, regard Angelalign as a benchmark in managing complex orthodontic cases. What's remarkable is that some competitors have even adopted elements from Angelalign's innovations, such as the angelButton™ system and the A6 mandibular advancement device.

Currently, Angelalign boasts a market capitalization of $2 billion, marked financial viability, and a solid balance sheet bolstered by a devoted global workforce. For orthodontists, Angelalign represents a steadfast partner in achieving exceptional clinical results over time.

Two judgments delivered on June 26, 2026, by the Intermediate People's Court in Zhengzhou, China, reaffirmed Angelalign's position by rejecting the plaintiff's patent infringement claims entirely. This string of favorable outcomes reinforces Angel's standing in the industry and showcases its resilience against ongoing legal challenges.

Future Prospects

As Angelalign continues its appeal process, stakeholders have good reason for confidence. The company aims to sustain its trajectory of global expansion, which has seen it establish a presence in over 60 countries and regions since its market entry in North America three years ago. The launch of a new 52,000 square foot manufacturing facility in the U.S. symbolizes Angelalign's commitment to meeting growing demand and advancing orthodontic solutions.

Angelalign invites interested parties to learn more about their legal proceedings and product offerings at www.angelaligner.com/legal-proceedings. The company was founded in 2003 and celebrates over two million smiles achieved globally, reinforcing its purpose to deliver cutting-edge orthodontic solutions with confidence.

In a world where dental care is paramount, Angelalign stands poised to face challenges head-on while driving innovation in orthodontic treatments, ensuring that both professionals and patients benefit from their dedication to excellence.